reference/33888360

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/33888360

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural\|Research Support, U.S. Gov't, Non-P.H.S.
issn	2379-3708
issueIdentifier	6
publicationName	JCI Insight
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_8a84060532d8b9418fd17a2962a3d068 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_eb4f340a1767b2ff28113b9d3c67834b http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_3a890853bfac877e53300ee0dd9c95cf http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_18cabf75b33eaa0b84af06e6401b5213 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_df123051b664f0602b70b6f14208b603
bibliographicCitation	Tsao LC, Crosby EJ, Trotter TN, Wei J, Wang T, Yang X, Summers AN, Lei G, Rabiola CA, Chodosh LA, Muller WJ, Lyerly HK, Hartman ZC. Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. JCI Insight. 2022 Mar 22;7(6). PMID: 35167491; PMCID: PMC8986081.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2136-0585 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e44ffd33797de4daf9c3cab07f8a767b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_66111056b36602915f7b98dad697bc8b http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4872-6711 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_054d3d447353f4fbd374b753df5aa584 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-6549-8207 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1027-8674 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce2c7ca562f343dd57e4ca835f3c5f63 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c79ddb2b19491d0c948f46b0a95f2ecd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8d3a47c9447913c46edfb44ef4a07c86 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6ec4ea87cefc23aed0cc7ee679c4a760 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83e47b32a5a21e1ffba5135d712557ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0063-4770
date	2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/35167491 https://pubmed.ncbi.nlm.nih.gov/PMC8986081 https://doi.org/10.1172/jci.insight.155636
isPartOf	https://portal.issn.org/resource/ISSN/2379-3708 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/44864
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis
discusses	http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0291428 http://id.nlm.nih.gov/mesh/M0466011 http://id.nlm.nih.gov/mesh/M0028048 http://id.nlm.nih.gov/mesh/M0024366
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D001943Q000473 http://id.nlm.nih.gov/mesh/D018719Q000378
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D051379 http://id.nlm.nih.gov/mesh/D010587 http://id.nlm.nih.gov/mesh/D015922 http://id.nlm.nih.gov/mesh/D000068878Q000627 http://id.nlm.nih.gov/mesh/D045744 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D000068878Q000494
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d294a627c5d0c2a686320df999909042 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_994c54dcb445c697192d154bd1f48884 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_93bd5ef2d3489c1bb9028f428c8194c8 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID19090 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID12259

Total number of triples: 60.